文献速递浆细胞疾病

1F10:靶向λ轻链淀粉样变的特异性单克隆抗体

1F10, a λ Light Chain Amyloid-Specific Monoclonal Antibody for Targeted Therapy of AL Amyloidosis.
PubMed 文献 · Blood · 2026-07-29

本文报道了新型高亲和力λ亚型特异性淀粉样结合单克隆抗体1F10的开发。1F10不与可溶性天然λ或κ轻链交叉反应,对λ AL淀粉样纤维具有优于birtamimab和anselamimab的结合亲和力,并显著增强抗体依赖性吞噬作用。在AL淀粉样瘤小鼠模型中,1F10显著加速λ淀粉样纤维的清除。

要点

  • 1F10为λ亚型特异性淀粉样结合单抗,不结合可溶性天然轻链。
  • 1F10对λ AL淀粉样纤维亲和力及ADP活性优于birtamimab和anselamimab。
  • 小鼠模型中1F10显著加速λ淀粉样纤维清除。

核心结论

  • 1F10是有前景的λ轻链淀粉样变亚型特异性免疫治疗候选抗体。

研究设计与样本

  • 临床前研究:开发新型单克隆抗体1F10并进行体外结合、吞噬及小鼠体内活性评估。

主要发现

  • 1F10对λ AL淀粉样纤维的结合亲和力优于birtamimab和anselamimab,并显著增强抗体依赖性吞噬作用。
  • 免疫组化证实1F10特异性结合患者组织活检来源的λ淀粉样沉积。
  • 在AL淀粉样瘤小鼠模型中,1F10显著加速λ淀粉样纤维的清除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Light chain (AL) amyloidosis is a fatal plasma cell dyscrasia characterized by the overproduction of misfolded l or k immunoglobulin light chains (LCs) produced by clonal plasma cells, which aggregate into amyloid fibrils that deposit in tissues and cause progressive organ damage. While current anti-plasma cell therapies reduce the production of new amyloidogenic LCs, pre-existing fibrils persist and continue to drive organ damage. Amyloid-targeting monoclonal antibodies birtamimab and anselamimab were developed and tested for active AL amyloid clearance; however, they failed to meet the primary endpoint in Phase 3 trials, presumably due to insufficient binding affinity for l LC amyloid, which occurs in ~80% of patients. Here, we reported the development of 1F10, a novel high-affinity l subtype-specific amyloid-binding monoclonal antibody that does not cross-react with soluble native l or k LCs. 1F10 exhibits superior binding affinity to l AL amyloid fibrils and significantly enhances antibody-dependent phagocytosis (ADP) of l AL amyloid compared with birtamimab and anselamimab. Specific binding of 1F10 to l amyloid is confirmed by immunohistochemical staining of patient-derived tissue biopsies. Importantly, 1F10 demonstrates robust in vivo activity, significantly accelerating the resolution of l amyloid fibrils in an AL amyloidoma mouse model. Together, these findings establish 1F10 antibody as a promising subtype-specific immunotherapeutic candidate for targeting l LC amyloid, addressing a critical unmet need for the majority of patients with AL amyloidosis.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Fu J, Hughes MS, Kalantarov GF, et al. 1F10, a λ Light Chain Amyloid-Specific Monoclonal Antibody for Targeted Therapy of AL Amyloidosis. Blood. 2026. PMID: 42526048. doi:10.1182/blood.2026033437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。